Skip to content

Study · Observational study · n = 584,236 · 2026

9 results

Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study.

Wu JY, Lee KW, Huang SC, Chang HY, Lin YM

BMC cardiovascular disorders9 Jul 2026

PMID42426654 (opens in a new tab)PMCIDPMC13632370 (opens in a new tab)DOI10.1186/s12872-026-06269-8 (opens in a new tab)PepBankPUB-42426654
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity, tirzepatide users had a lower risk of newly diagnosed aortic stenosis or aortic valve replacement than GLP-1 RA users.

    In plain wordsIn adults with obesity, tirzepatide use was linked to a lower risk of aortic valve disease or valve replacement than GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNewly diagnosed AS or AVR (composite)
    Study

    n = 584,236

    Comparator
    GLP-1 receptor agonists
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.9 ratio
    AS or AVR

    Source sentences

    Summary
    During follow-up, tirzepatide users had a significantly lower risk of AS or AVR compared with GLP-1 RA users (0.2% vs. 0.6%; HR 0.90, 95% CI 0.81-0.98; P = 0.022).
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity, tirzepatide was associated with a lower risk of newly diagnosed aortic stenosis than GLP-1 RAs.

    In plain wordsIn adults with obesity, tirzepatide use was linked to a lower risk of new aortic valve narrowing than GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNewly diagnosed aortic stenosis
    Study

    n = 584,236

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.9 ratio
    AS

    Source sentences

    Summary
    Tirzepatide was also associated with reduced risk of newly diagnosed AS (HR 0.90, 95% CI 0.81-0.99; P = 0.025)
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity, tirzepatide was associated with lower all-cause mortality than GLP-1 RAs.

    In plain wordsIn adults with obesity, tirzepatide use was linked to fewer deaths from any cause than GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 584,236

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.88 ratio
    all-cause mortality

    Source sentences

    Summary
    lower all-cause mortality (HR 0.88, 95% CI 0.81-0.95; P = 0.001).
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  4. 04HumanObservational studyOther

    In adults with obesity, tirzepatide showed no association with the negative-control outcome of skin cancer.

    In plain wordsIn adults with obesity, tirzepatide showed no link to skin cancer, which was used as a control check.

    Peptide
    Tirzepatide
    Outcome
    No significant changeNegative-control outcome (skin cancer)
    Study

    n = 584,236

    Comparator
    GLP-1 receptor agonists
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No association was observed for the negative-control outcome of skin cancer.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  5. 05HumanObservational studyEfficacy outcome

    Subgroup findings for AS or AVR were generally consistent, with stronger protective associations in women and adults aged 65 years or older.

    In plain wordsIn adults with obesity, the link to fewer aortic valve events looked stronger in women and in adults aged 65 or older.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSubgroup results by sex and age
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroup findings were generally consistent, with stronger protective associations observed in women and adults ≥ 65 years.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  6. 06HumanObservational studyEfficacy outcome

    In a sensitivity analysis against no treatment, tirzepatide was associated with lower risk of aortic stenosis or aortic valve replacement.

    In plain wordsCompared with no treatment, tirzepatide use was linked to a lower risk of aortic valve disease or valve replacement.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAS or AVR versus no treatment
    Study

    n: not reported in source

    Comparator
    No treatment
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a sensitivity analysis using a no-treatment comparator, tirzepatide was also associated with lower risks of AS/AVR, AS, AVR, and all-cause mortality; however, the mortality association was interpreted cautiously because of potential healthy-user and treatment-selection biases.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  7. 07HumanObservational studyEfficacy outcome

    In a sensitivity analysis against no treatment, tirzepatide was associated with lower risk of aortic stenosis.

    In plain wordsCompared with no treatment, tirzepatide use was linked to a lower risk of new aortic valve narrowing.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAortic stenosis versus no treatment
    Study

    n: not reported in source

    Comparator
    No treatment
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a sensitivity analysis using a no-treatment comparator, tirzepatide was also associated with lower risks of AS/AVR, AS, AVR, and all-cause mortality; however, the mortality association was interpreted cautiously because of potential healthy-user and treatment-selection biases.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  8. 08HumanObservational studyEfficacy outcome

    In a sensitivity analysis against no treatment, tirzepatide was associated with lower risk of aortic valve replacement.

    In plain wordsCompared with no treatment, tirzepatide use was linked to a lower risk of aortic valve replacement.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAortic valve replacement versus no treatment
    Study

    n: not reported in source

    Comparator
    No treatment
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a sensitivity analysis using a no-treatment comparator, tirzepatide was also associated with lower risks of AS/AVR, AS, AVR, and all-cause mortality; however, the mortality association was interpreted cautiously because of potential healthy-user and treatment-selection biases.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.
  9. 09HumanObservational studyEfficacy outcome

    In a sensitivity analysis against no treatment, tirzepatide was associated with lower all-cause mortality, which the authors interpreted cautiously because of healthy-user and treatment-selection bias.

    In plain wordsCompared with no treatment, tirzepatide use was linked to fewer deaths, but the authors warn that bias may explain part of this.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality versus no treatment
    Study

    n: not reported in source

    Comparator
    No treatment
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a sensitivity analysis using a no-treatment comparator, tirzepatide was also associated with lower risks of AS/AVR, AS, AVR, and all-cause mortality; however, the mortality association was interpreted cautiously because of potential healthy-user and treatment-selection biases.
    2 context sentences
    Summary · context
    Adults ≥ 18 years with obesity who initiated tirzepatide or GLP-1 RAs between 2022 and 2025 were identified.
    Summary · context
    After PSM, 584,236 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.